Login/Sign Up
Ryverna Solution for Infusion
Ryverna Solution for Infusion is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. It contains Crizanlizumab-tmca, which works by binding to the protein P-selectin in the blood. This protein is responsible for the adhesion of blood cells. By inhibiting P-selectin, blood cell limitations are avoided, and blood supply throughout the body is improved. Common side effects of this medicine may include Infusion site reactions, nausea, arthralgia (pain in a joint), back pain, and pyrexia (fever).
₹16400*
MRP ₹20000
18% off
₹17000*
MRP ₹20000
15% CB
₹3000 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Whats That
Ryverna Solution for Infusion belongs to the group of medicines called monoclonal antibodies, which is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells obstruct blood flow to the point where tissues are deprived of oxygen. This, in turn, causes an inflammatory reaction. The outcome is severe pain, which can affect any part of the body but is most typically felt in the back, chest, or extremities.
Ryverna Solution for Infusion contains Crizanlizumab-tmca, which works by blocking certain blood cells from interacting.
Ryverna Solution for Infusion will be administered by a healthcare professional; do not self-administer. Your doctor will decide the dose and duration based on your medical condition. In some cases, Ryverna Solution for Infusion may cause Infusion site reactions, nausea, arthralgia (pain in a joint), back pain, and pyrexia (fever). Most of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen.
Before taking the Ryverna Solution for Infusion, let your doctor know about all your medical conditions, sensitivities, and medications you are using. Ryverna Solution for Infusion may cause fetal harm. So, inform your doctor if you are pregnant and planning to become pregnant. Do not breastfeed while on medication unless recommended by the doctor. Ryverna Solution for Infusion is not recommended for children below 16 years as the safety and effectiveness have not been established. Consumption of alcohol is not recommended while on therapy.
Ryverna Solution for Infusion contains Crizanlizumab-tmca, which belongs to the group of medicines called monoclonal antibodies and is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Crizanlizumab-tmca which works by binding to the protein P-selectin in the blood. This protein is responsible for the adhesion of blood cells. By inhibiting P-selectin, blood cell limitations are avoided, and blood supply throughout the body is improved.
Before using the Ryverna Solution for Infusion, inform your doctor about your medical conditions (e.g., pregnancy, nursing, any scheduled surgery, etc.), sensitivities (allergic reactions to foods and medicines), and medications you are taking. Other drugs (especially corticosteroids) or supplements should not be taken with Ryverna Solution for Infusion unless prescribed by a doctor. Do not miss any doses and finish the entire course of medicine. Stopping the drug too soon may cause the infection to reoccur or worsen.
Drug-Drug Interactions: Ryverna Solution for Infusion may interact with a medication used to treat a certain form of myasthenia gravis (Efgartigimod alfa, Rozanolixizumab) and corticosteroid medications.
Drug-Food Interactions: Avoid the consumption of alcohol while taking Ryverna Solution for Infusion.
Drug-Disease Interactions: Caution is advised if used Ryverna Solution for Infusion in patients with renal or hepatic impairment.
A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells obstruct blood flow to the point where tissues are deprived of oxygen. This, in turn, causes an inflammatory reaction. The outcome is severe pain, which can affect any body part but is most typically felt in the back, chest, or extremities.
Alcohol
Caution
You are recommended to avoid alcohol consumption while taking Ryverna Solution for Infusion. It could lead to unpleasant side effects.
Pregnancy
Caution
Ryverna Solution for Infusion may cause fetal harm. Therefore, please inform your doctor if you are pregnant; your doctor will weigh the benefits and potential risks before prescribing this medicine.
Breast Feeding
Caution
It is not known if this medicine passes into your breast milk. Inform your doctor if you are breastfeeding or plan to breastfeed. Your doctor decides the best way to feed your baby during treatment with Ryverna Solution for Infusion.
Driving
Caution
Ryverna Solution for Infusion does not impact your ability to drive or use machinery.
Liver
Caution
Caution should be exercised while using Ryverna Solution for Infusion in patients with liver disease. So, inform your doctor before receiving the Ryverna Solution for Infusion if you have a history of liver diseases/conditions. Your doctor will prescribe only if the benefits outweigh the risks.
Kidney
Caution
Caution should be exercised while using Ryverna Solution for Infusion in patients with kidney disease. So, inform your doctor before receiving the Ryverna Solution for Infusion if you have a history of kidney diseases/conditions. Your doctor will prescribe only if the benefits outweigh the risks.
Children
Unsafe
Ryverna Solution for Infusion is not recommended for children below 16 years as the safety and effectiveness have not been established.
Country of origin
We provide you with authentic, trustworthy and relevant information